Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Novel Human Monoclonal Antibody Cures Leukemia in Mouse Model

By BiotechDaily International staff writers
Posted on 01 Apr 2013
A novel monoclonal antibody that binds to the intracellular WT1 protein, which is expressed in many types of cancer but only rarely in normal cells, was used to cure leukemia in a mouse model that mimicked the human disease.

The Wilms' tumor 1 gene (WT1) has been identified as a tumor suppressor gene involved in the etiology of Wilms' tumor. Approximately 10% of all Wilms' tumors carry mutations in the WT1 gene. Alterations in this gene have also been observed in other tumor types, such as leukemia, mesothelioma, and desmoplastic small round cell tumor. Dependent on the tumor type, WT1 proteins might function either as tumor suppressor proteins or as survival factors. Mouse models have proven the critical importance of WT1 expression for the development of several organs, including the kidneys, the gonads, and the spleen. The WT1 proteins seem to perform two main functions; they regulate the transcription of a variety of target genes and may be involved in post-transcriptional processing of RNA.

Investigators at Memorial Sloan-Kettering Cancer Center (New York, NY, USA) and the biotech company Eureka Therapeutics (Emeryville, CA, USA) used phage display technology to develop a fully human “T cell receptor-like” monoclonal antibody (mAb), ESK1, specific for the WT1 RMF peptide/HLA-A0201 complex.

They reported in the March 13, 2013, online edition of the journal Science Translational Medicine that ESK1 bound to several leukemia and solid tumor cell lines and primary leukemia cells, in a WT1- and HLA-A0201-restricted manner. ESK1 mediated antibody-dependent human effector cell cytotoxicity in vitro. Low doses of naked ESK1 antibody cleared established, disseminated, human acute lymphocytic leukemia and Philadelphia chromosome-positive leukemia in nonobese diabetic/severe combined immunodeficient mouse models. At therapeutic doses, no toxicity was seen in HLA-A0201 transgenic mice.

“This is a new approach for attacking WT1, an important cancer target, with an antibody therapy. This is something that was previously not possible,” said senior author Dr. David A. Scheinberg, professor of molecular pharmacology at the Memorial Sloan-Kettering Cancer Center. “There has not been a way to make small molecule drugs that can inhibit WT1 function. Our research shows that you can use a monoclonal antibody to recognize a cancer-associated protein inside a cell, and it will destroy the cell.”

“ESK1 represents a paradigm change for the field of human monoclonal antibody therapeutics,” said Dr. Cheng Liu, president and CEO of Eureka Therapeutics. “This research suggests that human antibody therapy is no longer limited to targeting proteins present outside cancer cells, but can now target proteins within the cancer cell itself.”

Related Links:
Memorial Sloan-Kettering Cancer Center
Eureka Therapeutics


Channels

Drug Discovery

view channel

Curcumin Used to Treat Alzheimer’s Disease

Curcumin, a natural substance found in the spice turmeric, has been used by many Asian cultures for centuries. Now, new research suggests that a close chemical analog of curcumin has properties that may make it useful as a treatment for Alzheimer’s disease. “Curcumin has demonstrated ability to enter the brain, bind... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.